Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

This study is testing a new drug called NEO-811 for people with advanced kidney cancer (specifically, clear cell renal cell carcinoma) that has spread or cannot be surgically removed, and whose cancer has progressed after standard treatments. The study is in early phases, looking at safety and the right dose. **You may be eligible if...** - You have locally advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) - Your cancer has gotten worse on standard therapies, or you have declined those treatments - You are in good enough overall health (ECOG performance score 0 or 1 — able to carry out daily activities) - Your life expectancy is at least 12 weeks - You have measurable cancer on scans - You can provide a tumor tissue sample (either a new biopsy or an archived sample) **You may NOT be eligible if...** - You have a different subtype of kidney cancer (not clear cell) - You have serious heart, liver, or kidney problems - You have untreated brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.